-
1
-
-
0037070232
-
Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: A randomised crossover trial
-
Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomised crossover trial. JAMA 2002;287:719- 25.
-
(2002)
JAMA
, vol.287
, pp. 719-725
-
-
Arruda-Olson, A.M.1
Mahoney, D.W.2
Nehra, A.3
-
2
-
-
0346333034
-
Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease
-
DeBusk RF, Pepine CJ, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004;93:147-53.
-
(2004)
Am J Cardiol
, vol.93
, pp. 147-153
-
-
DeBusk, R.F.1
Pepine, C.J.2
Glasser, D.B.3
-
3
-
-
3543120077
-
Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: A randomized, double-blind, placebo-controlled crossover trial
-
Ghofrani HA, Reichenberger F, Kohstall MG, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004;141:169-77.
-
(2004)
Ann Intern Med
, vol.141
, pp. 169-177
-
-
Ghofrani, H.A.1
Reichenberger, F.2
Kohstall, M.G.3
-
5
-
-
0242460582
-
Cardiovascular effects of tadalafil in patients on common antihypertensive therapies
-
Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003;92:47-57M.
-
(2003)
Am J Cardiol
, vol.92
-
-
Kloner, R.A.1
Mitchell, M.2
Emmick, J.T.3
-
6
-
-
33744916246
-
Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia
-
Hsu AR, Barnholt KE, Grundmann NK, et al. Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. J Appl Physiol 2006;100:2031-40.
-
(2006)
J Appl Physiol
, vol.100
, pp. 2031-2040
-
-
Hsu, A.R.1
Barnholt, K.E.2
Grundmann, N.K.3
-
7
-
-
17344362498
-
Effects of sildenafil on the human response to acute hypoxia and exercise
-
Ricart A, Maristany J, Fort N, et al. Effects of sildenafil on the human response to acute hypoxia and exercise. High Alt Med Biol 2005;6:43-9.
-
(2005)
High Alt Med Biol
, vol.6
, pp. 43-49
-
-
Ricart, A.1
Maristany, J.2
Fort, N.3
-
8
-
-
0037183551
-
Sildenafil effects on exercise, neurohormonal activation and erectile dysfunction in congestive heart failure: A double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction
-
Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106:1097-103.
-
(2002)
Circulation
, vol.106
, pp. 1097-1103
-
-
Bocchi, E.A.1
Guimaraes, G.2
Mocelin, A.3
-
9
-
-
4644232338
-
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study
-
Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44:1488- 96.
-
(2004)
J Am Coll Cardiol
, vol.44
, pp. 1488-1496
-
-
Ghofrani, H.A.1
Voswinckel, R.2
Reichenberger, F.3
-
10
-
-
0033609027
-
Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure
-
Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999;99:2113-17.
-
(1999)
Circulation
, vol.99
, pp. 2113-2117
-
-
Katz, S.D.1
Khan, T.2
Zeballos, G.A.3
-
11
-
-
0242349756
-
Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension
-
Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9.
-
(2003)
Circulation
, vol.108
, pp. 2066-2069
-
-
Michelakis, E.D.1
Tymchak, W.2
Noga, M.3
-
12
-
-
0034642329
-
Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise
-
Traverse JH, Chen YJ, Du R, et al. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. Circulation 2000;102:2997-3002.
-
(2000)
Circulation
, vol.102
, pp. 2997-3002
-
-
Traverse, J.H.1
Chen2
YJ, D.R.3
-
13
-
-
0026327575
-
Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues
-
Ahn HS, Foster M, Cable M, et al. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991;308:191-7.
-
(1991)
Adv Exp Med Biol
, vol.308
, pp. 191-197
-
-
Ahn, H.S.1
Foster, M.2
Cable, M.3
-
14
-
-
0242625934
-
An update on the PDE-5 inhibitors (PDE-5i)
-
McCullough AR. An update on the PDE-5 inhibitors (PDE-5i). J Androl 2003;24:S52-8.
-
(2003)
J Androl
, vol.24
-
-
McCullough, A.R.1
-
15
-
-
22644440012
-
3,5-Cyclic nucleotide phosphodiesterase 11A: Localization in human tissues
-
Loughney K, Taylor J, Florio VA. 3,5-Cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res 2005;17:320-5.
-
(2005)
Int J Impot Res
, vol.17
, pp. 320-325
-
-
Loughney, K.1
Taylor, J.2
Florio, V.A.3
-
16
-
-
0030154874
-
Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
-
Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
-
(1996)
Int J Impot Res
, vol.8
, pp. 47-52
-
-
Boolell, M.1
Allen, M.J.2
Ballard, S.A.3
-
17
-
-
0034868820
-
The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial
-
Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13:192-9.
-
(2001)
Int J Impot Res
, vol.13
, pp. 192-199
-
-
Porst, H.1
Rosen, R.2
Padma-Nathan, H.3
-
18
-
-
0036332629
-
Pharmacology of phosphodiesterase-5 inhibitors
-
Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56:453-9.
-
(2002)
Int J Clin Pract
, vol.56
, pp. 453-459
-
-
Corbin, J.D.1
Francis, S.H.2
-
19
-
-
22244447089
-
Recreational use and misuse of phosphodiesterase 5 inhibitors
-
Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc 2005;45:63-72.
-
(2005)
J Am Pharm Assoc
, vol.45
, pp. 63-72
-
-
Smith, K.M.1
Romanelli, F.2
-
20
-
-
39449092563
-
-
max, aerobic, and anaerobic thresholds in normoxia. Int J Sports Med 2007; epub ahead of print.
-
max, aerobic, and anaerobic thresholds in normoxia. Int J Sports Med 2007; epub ahead of print.
-
-
-
-
21
-
-
0025249867
-
Assessment of peak oxygen consumption, lactate and ventilatory thresholds and correlation with resting and exercise hemodynamic data in chronic congestive heart failure
-
Metra M, Raddino B, Dei Cas L, et al. Assessment of peak oxygen consumption, lactate and ventilatory thresholds and correlation with resting and exercise hemodynamic data in chronic congestive heart failure. Am J Cardiol 1990;65:1127-33.
-
(1990)
Am J Cardiol
, vol.65
, pp. 1127-1133
-
-
Metra, M.1
Raddino, B.2
Dei Cas, L.3
-
23
-
-
0036943348
-
How anaerobic is the Wingate Anaerobic Test for humans?
-
Beneke R, Pollmann C, Bleif I, et al. How anaerobic is the Wingate Anaerobic Test for humans? Eur J Appl Physiol 2002;87:388-92.
-
(2002)
Eur J Appl Physiol
, vol.87
, pp. 388-392
-
-
Beneke, R.1
Pollmann, C.2
Bleif, I.3
-
24
-
-
0034740582
-
Evaluation of the Accusport lactate analyzer
-
Bishop D. Evaluation of the Accusport lactate analyzer. Int J Sports Med 2001;22:525-30.
-
(2001)
Int J Sports Med
, vol.22
, pp. 525-530
-
-
Bishop, D.1
-
25
-
-
0038458914
-
Warm up II. Performance changes following active warm up and how to structure the warm up
-
Bishop D. Warm up II. Performance changes following active warm up and how to structure the warm up. Sports Med 2003;33:483-98.
-
(2003)
Sports Med
, vol.33
, pp. 483-498
-
-
Bishop, D.1
-
28
-
-
26844453717
-
Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T
-
Hassan MA, Ketat AF. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 2005;6:5-10.
-
(2005)
BMC Pharmacol
, vol.6
, pp. 5-10
-
-
Hassan, M.A.1
Ketat, A.F.2
-
29
-
-
29544452788
-
Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors
-
Jackson G. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am J Cardiol 2005;96:32-6M.
-
(2005)
Am J Cardiol
, vol.96
-
-
Jackson, G.1
-
30
-
-
0141505057
-
-
Abdollahi M, Chan TS, Subrahmanyam V, et al. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenosis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 2003;252:205-11.
-
Abdollahi M, Chan TS, Subrahmanyam V, et al. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenosis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 2003;252:205-11.
-
-
-
|